Analyst Consensus ?
ConsensusHold22 ratings
Bullish940.9%
Neutral1254.6%
Bearish14.5%
DaVita Inc. · DVA · FY2026 Q1 · Calendar Q2 2026
DaVita Q1 2026: EPS Beat of 19%, Guidance Raised on Volume and AI Gains
DaVita's Q1 2026 results exceeded consensus on both lines, with adjusted EPS of $2.87 versus a $2.41 estimate (a 19% surprise) and revenue of $3.42 billion versus $3.36 billion expected. The beat was driven by treatment volume running slightly ahead of forecast, helped by improving mortality trends and patient transfers from Fresenius clinic closures. Management raised full-year guidance for both adjusted operating income (to $2.15-$2.25 billion from $2.085-$2.235 billion) and EPS (to $14.10-$15.20 from $13.60-$15.00), reflecting confidence in sustained volume recovery and operational efficiency from AI and technology investments. The stock surged 23.5% on the report, well ahead of the benchmark's 1.4% move. The quarter marks a shift from the prior quarter's maintained guidance and flat volume narrative toward a more constructive trajectory, though management flagged ACA enrollment…
Reported After market closeNYSEHealthcare
$15.33B market cap
100quality score
Company context
Snapshot as of publicationDaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities.…
Earnings scorecard
Reported versus consensus
Reported EPS
$2.87
Consensus $2
EPS surprise
+19.1%
Reported versus consensus
Reported revenue
$3.42B
Consensus $3.36B
Revenue surprise
+1.8%
Reported versus consensus
Earnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$238.86Previous close
$81Low
$181.9Average
$270High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Jul 31, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Truist Securities | Hold | Hold | Maintain | Jul 14, 2026 |
| UBS | Buy | Buy | Maintain | Jul 10, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 9, 2026 |
| TD Cowen | Hold | Hold | Maintain | May 11, 2026 |
| Deutsche Bank | Buy | Hold | Upgrade | May 6, 2026 |
| B of A Securities | Underperform | Underperform | Maintain | Sep 10, 2025 |
| Bernstein | Market Perform | Market Perform | Maintain | May 15, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Feb 23, 2023 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Oct 29, 2021 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | May 6, 2020 |
| Goldman Sachs | Buy | Neutral | Upgrade | Jan 24, 2020 |
| JP Morgan | Neutral | Neutral | Maintain | Dec 20, 2019 |
| Raymond James | Market Perform | Outperform | Downgrade | Nov 7, 2019 |
| Baird | Neutral | Neutral | Maintain | Nov 6, 2019 |
| William Blair | Market Perform | Outperform | Downgrade | Sep 11, 2019 |
| Bank of America | Buy | Neutral | Upgrade | Jan 4, 2018 |
| Citigroup | Buy | Neutral | Upgrade | Dec 11, 2017 |
| Jefferies | Hold | Buy | Downgrade | Jun 26, 2017 |
| Keybanc | Hold | Buy | Downgrade | Sep 17, 2014 |
| Atlantic Equities | Overweight | Overweight | Maintain | Oct 10, 2013 |
| Feltl & Co. | Buy | Buy | Maintain | Oct 31, 2012 |
| Bank oferica | Buy | Buy | Maintain | Apr 5, 2012 |
Named analyst price targets
Upside is calculated against the persisted previous close $238.86. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Truist Financial | Analyst unavailable | $250 | $235.58 | +4.7% | Jul 14, 2026 |
| UBS | Analyst unavailable | $270 | $229.48 | +13.0% | Jul 10, 2026 |
| Barclays | Analyst unavailable | $218 | $234.31 | -8.7% | Jul 8, 2026 |
| Truist Financial | Analyst unavailable | $205 | $194.38 | -14.2% | May 8, 2026 |
| Barclays | Andrew Mok | $194 | $193.88 | -18.8% | May 7, 2026 |
| Deutsche Bank | Pito Chickering | $220 | $157.04 | -7.9% | May 6, 2026 |
| Truist Financial | Analyst unavailable | $158 | $144.42 | -33.9% | Feb 5, 2026 |
| UBS | Analyst unavailable | $190 | $134.73 | -20.5% | Feb 4, 2026 |
| Barclays | Analyst unavailable | $158 | $111.19 | -33.9% | Feb 3, 2026 |
| Barclays | Analyst unavailable | $143 | $126.56 | -40.1% | Oct 30, 2025 |
| Truist Financial | David MacDonald | $140 | $123.36 | -41.4% | Oct 14, 2025 |
| Barclays | Andrew Mok | $149 | $127.89 | -37.6% | Oct 9, 2025 |
| Truist Financial | David MacDonald | $148 | $129.54 | -38.0% | Aug 8, 2025 |
| Bernstein | Lisa Bedell Clive | $184 | $142.4 | -23.0% | Feb 21, 2025 |
| Bank of America Securities | Kevin Fischbeck | $145 | $133.53 | -39.3% | Aug 7, 2024 |
| Barclays | Andrew Mok | $150 | $134.45 | -37.2% | May 6, 2024 |
| Barclays | Sarah James | $81 | $70.54 | -66.1% | Oct 31, 2022 |
| UBS | Andrew Mok | $117 | $93.1 | -51.0% | Aug 19, 2022 |
| Truist Financial | David MacDonald | $90 | $79.44 | -62.3% | Jun 28, 2022 |
Track every rating change on DVA the moment it posts. Free to start.
Start freeMarket reaction
event-close to next-session close
Stock move
+23.5%
Event window
SPY move
+1.4%
Same window
Abnormal move
+22.1%
Stock minus SPY
Volume
4.3×
Versus trailing sessions
Subsequent drift
-0.9%
Up to 20 sessions
DVASPY benchmark
Follow DVA with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
From Q4 2025 to Q1 2026, DaVita shifted from maintaining to raising guidance. Treatment volume, which was flat in the prior quarter, showed growth driven by better mortality trends and Fresenius clinic closure transfers contributing roughly half of the projected 25-50 bps annual volume growth. The Integrated Kidney Care program, which achieved first-time profitability in 2025, continued to strengthen, with DaVita recording the highest total aggregate savings among CMS CKCC participants at a 4.5% improvement in gross savings rate. Technology investment took on greater prominence with the deployment of ScheduleHub, an AI-driven real-time scheduling tool, complementing prior-quarter clinical initiatives around vaccination, GLP-1 adoption, and advanced dialysis technologies. The Elara Caring partnership and $200 million minority investment announced in Q4 2025 were not highlighted as new developments this quarter.
Guidance delta
Full-year 2026 guidance was raised. Adjusted operating income moved from $2.085-$2.235 billion to $2.15-$2.25 billion, and adjusted EPS from $13.60-$15.00 to $14.10-$15.20. The prior quarter's guidance sentiment was 'maintained'; this quarter's is 'raised.'
Key takeaways
- EPS of $2.87 beat the $2.41 consensus estimate by 19%, while revenue of $3.42 billion topped the $3.36 billion estimate by 1.8%.
- Full-year guidance was raised, with adjusted operating income now $2.15-$2.25 billion and EPS $14.10-$15.20, up from $2.085-$2.235 billion and $13.60-$15.00.
- Treatment volume growth outlook was upgraded, supported by better mortality trends and patient transfers from Fresenius clinic closures contributing roughly half of the projected 25-50 bps annual growth.
- DaVita achieved the highest total aggregate savings among CMS CKCC participants, with a 4.5% improvement in gross savings rate in its Integrated Kidney Care program.
- AI and technology investments, including the ScheduleHub scheduling tool, are delivering productivity gains across clinical and operational functions.
Management priorities
- Expand AI applications across clinical, operational, and business use cases.
- Capture additional market share from Fresenius clinic closures.
- Continue investment in IT systems, EMR modernization, and digital tools.
- Maintain disciplined capital allocation with ongoing share repurchases.
Related earnings events
HealthcareHCA · FY2026 Q2 · Calendar Q3 2026HCA Q2 2026: Payer-Mix Shift Hits EBITDA, Florida Medicaid Boosts, $7B Capex UnveiledWST · FY2026 Q2 · Calendar Q3 2026West Pharmaceutical Q2 2026: EPS and Revenue Beat, Guidance Raised AgainDGX · FY2026 Q2 · Calendar Q3 2026Quest Diagnostics Beats on Volume and AI Automation, Raises Full-Year Guidance
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-07-31T09:32:31.414797+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-31T09:32:31.411996+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.